| __timestamp | MannKind Corporation | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 15635076 |
| Thursday, January 1, 2015 | 29674000 | 23943601 |
| Friday, January 1, 2016 | 14917000 | 23689111 |
| Sunday, January 1, 2017 | 14118000 | 41006114 |
| Monday, January 1, 2018 | 8737000 | 51379106 |
| Tuesday, January 1, 2019 | 6900000 | 32705593 |
| Wednesday, January 1, 2020 | 6248000 | 53274000 |
| Friday, January 1, 2021 | 12312000 | 85352000 |
| Saturday, January 1, 2022 | 19721000 | 51999000 |
| Sunday, January 1, 2023 | 31283000 | 59471000 |
Cracking the code
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Summit Therapeutics Inc. and MannKind Corporation have shown contrasting trends in their R&D investments.
From 2014 to 2023, Summit Therapeutics increased its R&D expenses by approximately 280%, peaking in 2021 with a 550% rise compared to 2014. This surge underscores Summit's aggressive pursuit of new therapies. In contrast, MannKind's R&D spending saw a significant decline of about 69% from its 2014 peak, reflecting a strategic shift or potential financial constraints.
These trends highlight the dynamic nature of the biotech industry, where strategic decisions on R&D can significantly impact a company's future. As investors and stakeholders evaluate these companies, understanding their R&D trajectories offers valuable insights into their long-term growth potential.
Comparing Innovation Spending: Pfizer Inc. and Summit Therapeutics Inc.
Research and Development: Comparing Key Metrics for Biogen Inc. and Summit Therapeutics Inc.
Research and Development: Comparing Key Metrics for United Therapeutics Corporation and Summit Therapeutics Inc.
Viatris Inc. or MannKind Corporation: Who Invests More in Innovation?
Research and Development Investment: Summit Therapeutics Inc. vs Geron Corporation
Summit Therapeutics Inc. or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Summit Therapeutics Inc. and Viridian Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Grifols, S.A. vs MannKind Corporation: Strategic Focus on R&D Spending
R&D Insights: How Catalyst Pharmaceuticals, Inc. and MannKind Corporation Allocate Funds
Amphastar Pharmaceuticals, Inc. or MannKind Corporation: Who Invests More in Innovation?
Comparing Innovation Spending: MannKind Corporation and Viridian Therapeutics, Inc.